Company intelligence / Profile preview
Lin BioScience, Inc.
Taipei City, Taiwanlinbioscience.com ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
LBS-007 received FDA Fast Track Designation for acute myeloid leukemia treatment in November 2024. Currently conducting a phase 1/2 trial in patients with relapsed or resistant acute leukemias in the US, Australia, and Taiwan. LBS-008 has initiated phase 3 trials for Stargardt disease.
- Therapeutic areas
- GastroenterologyOncologyOphthalmologyEndocrinologyHematology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
NIH Blueprint Program (BPN)Taiwan Industrial Development Bureau's Innovation Platform Program
Beyond the preview
Go deeper on Lin BioScience, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lin BioScience, Inc..